Defunct Company
Total Trials
15
As Lead Sponsor
13
As Collaborator
2
Total Enrollment
975
NCT00417287
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 2006
Completion: Apr 30, 2009
NCT00522652
Phase I Trial of PX-478
Phase: Phase 1
Start: Aug 31, 2007
Completion: May 31, 2010
NCT00726583
Phase I Trial of Oral PX-866
Start: Jun 30, 2008
Completion: Sep 30, 2011
NCT00736372
A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
Completion: Aug 31, 2009
NCT01204099
Study of PX-866 and Docetaxel in Solid Tumors
Phase: Phase 1/2
Start: Sep 30, 2010
Completion: Feb 28, 2014
NCT01252628
Phase 1 and 2 Study of PX-866 and Cetuximab
Start: Dec 31, 2010
Completion: Jan 31, 2014
NCT01259869
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Role: Collaborator
Start: Apr 1, 2011
Completion: Feb 13, 2015
NCT01408316
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
Start: Jul 31, 2011
Completion: Jan 31, 2012
NCT01616199
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Start: Aug 31, 2012
Completion: Mar 31, 2015
NCT01978964
Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors
Start: Nov 30, 2012
Completion: Mar 31, 2016
NCT01556789
Phase 1 Study of ONT-10 in Patients With Solid Tumors
Start: Mar 31, 2013
Completion: Sep 30, 2015
NCT02270372
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
Start: Nov 30, 2014
Completion: Jun 30, 2016
NCT03054363
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Start: Nov 27, 2017
Completion: Feb 7, 2023
NCT03758339
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
Start: Dec 30, 2017
Completion: Jan 30, 2018
NCT05070702
First in Human Study of CT-1500 in Healthy Participants
Start: Nov 8, 2021
Completion: Jul 7, 2022